Marinus Pharmaceuticals, Inc. (MRNS) financial statements (2021 and earlier)

Company profile

Business Address 5 RADNOR CORPORATE CENTER SUITE 500
RADNOR, PA 19087
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments140927353305650
Cash and cash equivalents139916834265250
Short-term investments1152044 
Contract with customer, asset2  
Other undisclosed current assets5211020
Total current assets:146947454305850
Noncurrent Assets
Property, plant and equipment2211100
Long-term investments and receivables   5 1 
Long-term investments   5 1 
Other noncurrent assets22   00
Total noncurrent assets:4516120
TOTAL ASSETS:150997561316050
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11873552
Accounts payable2321331
Accrued liabilities9542222
Employee-related liabilities      0
Debt    42 
Other undisclosed current liabilities      (0)
Total current liabilities:11873872
Noncurrent Liabilities
Long-term debt and lease obligation    257
Long-term debt, excluding current maturities    257
Liabilities, other than long-term debt33 0000
Accounts payable and accrued liabilities33 0000
Total noncurrent liabilities:33 0257
Total liabilities:13117310139
Temporary equity, carrying amount 28     
Stockholders' equity
Stockholders' equity attributable to parent137606858214741
Preferred stock4      
Common stock0000000
Additional paid in capital445295250203147144113
Accumulated other comprehensive loss  (0)(0)   
Accumulated deficit(312)(236)(181)(145)(126)(97)(72)
Total stockholders' equity:137606858214741
TOTAL LIABILITIES AND EQUITY:150997561316050

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(70)(54)(37)(19)(28)(24)(12)
Other undisclosed operating income2   000
Operating loss:(68)(54)(37)(19)(28)(24)(12)
Nonoperating income0010   
Investment income, nonoperating0010   
Other nonoperating expense(0)(0)(0)(0)   
Interest and debt expense   (0)(0)(0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes0(0)(0)(0)   
Net loss:(67)(54)(37)(19)(29)(25)(12)
Other undisclosed net income attributable to parent    001
Net loss attributable to parent:(67)(54)(37)(19)(29)(25)(11)
Preferred stock dividends and other adjustments(9)     (3)
Net loss available to common stockholders, diluted:(76)(54)(37)(19)(29)(25)(13)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(67)(54)(37)(19)(29)(25)(12)
Comprehensive loss:(67)(54)(37)(19)(29)(25)(12)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  0(0)   
Comprehensive loss, net of tax, attributable to parent:(67)(54)(37)(19)(29)(25)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: